Sequent Scientific Ltd.
Snapshot View

293.90 -3.15 ▼-1.1%

30 July 2021, 04:00:00 P.M.
Volume: 32,875

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.sequent.in
Financial Indicators
Market Cap 7,299.62 Cr.
Earnings per share (EPS) 3.84 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 76.48 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 29.30 Trailing Twelve Months Ending 2021-03
Price to Book Value 10.03 Calculated using Price: 293.90
Dividend Yield 0.17 Period Ending 2020-03
No. of Shares Subscribed 24.84 Cr. 248,370,995 Shares
FaceValue 2
Company Profile

Sequent Scientific earlier known as P I Drugs & Pharmaceuticals is an integrated  pharmaceutical company. Hon'ble High Court of Bombay approved the Scheme of Amalgamation of company with P I Drugs & Pharmaceuticals Ltd. Pursuant to the Scheme of Amalgamation as approved by the Honourable High Court Bombay vide its order dated June 16, 2009 Company  made requisite application to the Registrar of Companies Mumbai for change of its name from PI Drugs & Pharmaceuticals Ltd. to Sequent Scientific Ltd. Accordingly Registrar of Companies approved the application and issued fresh Certificate of Incorporation consequent upon change in name dated October 27, 2009 and with effect from the date the name of Company  changed to Sequent Scientific Ltd.

SeQuent is looking towards the future with courage and confidence, because of the critical role it can play to help make a difference in global economic progress and social wellbeing. Ever since inception in 2002 SeQuent has emerged as an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation) and Human health (API).

It has branded its Animal Health business as Alivira Animal Health with a singular focus to create value in the global animal health space. We cater to unaddressed global market requirements and focus on products for livestock, poultry and companion animals.

P I Drugs & Pharmaceuticals Ltd. established in 1991 was a leading manufacturer, exporter of specialized quality formulations having an objective of fulfilling the diverse demands of pharmaceutical industry.

Business area

It is  focused on the development and supply of high-value, low-volume niche and complex APIs, with a wide presence across therapies like anti-malarial, anthelmintics, anti-infective, antiviral, CNS and dermatology.

Sequent has invested in facilities with an objective of creating an integrated, flexible unit capable of manufacturing several niche & complex APIs. The manufacturing facalities are capable of meeting the growing demand of our key products in the USFDA and WHO regulated markets.

ALIVIRA ANIMAL HEALTH
Alivira is one of the world's leading producers of Animal Health APIs, and it is gradually emerging as a powerhouse in the global animal health business. The brand is strengthened by best-in-class manufacturing capacities, robust product portfolio, wide market presence and cutting-edge R&D capabilities.

Alivira has state-of-the-art API manufacturing facility at Vizag with a present production of 1,000 MT with scalable capacities. Alivira is set to cater to the growing global API requirements.

Alivira's formulation business has been strengthened by its acquisition in Provet, Turkey. With this we have a formulation facility in Ambernath. We are using in-licensing to strengthen our product portfolio and M&A's to widen our market coverage.

The therapies targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology.

Product range of the company includes:

  • Aciclovir Sodium
  •  Albendazole
  •  Artemether
  •  Artesunate
  •  Amyl Meta Cresol
  •  Citicoline Sodium
  •  Colchicine
  •  Dihydroartemisinin
  •  Ertapenem 
  •  Etomidate
  •  Hydralazine Hcl
  • Imiquimod
  • Indomethacin Sodium
  • DL-Selenomethionine  
  • Lumefantrine
  • Methoxsalen
  • Midazolam
  • Mivacurium Chloride 
  • Oseltamivir Phosphate
  • Piperaquine Phosphate
  • Praziquantel
  • Rifaximin   
  • Succinyl Choline Chloride
  • Warfarin

Milestones

2013 -Sequent receives US FDA Approval for ITS API Drug Manufacturing Facility at Mangalore. -Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd announce Joint Venture to Create Leading Animal Health Company.
2014 -SeQuent Scientific Limited announces completion of Sale of Specialty Chemicals division to Songwon Industrial Group. -Sequent Scientific to acquire the business of Arvee Synthesis Acquisition to provide impetus to Human API business. -Sequent Scientific - Updates - Alivira completes acquisition of majority stake in Provet Veterinary Products AS, Turkey.
2015 -SeQuent Scientific to acquire Animal Health business of Lyka Exports -SeQuent Scientific inaugurates new Analytical Services Centre at Bengaluru
2016 - SeQuent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormone -Sequent Scientific commences production in Vizag facility

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.06%
1 Week
-0.02%
1 Month
-6.00%
3 Month
+0.86%
6 Month
+40.05%
1 Year
+152.17%
2 Year
+329.99%
5 Year
+128.27%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -1.19 -62.91 -201.83 -28.10 -3.35 -1.74 54.15 8.63 11.58
Return on Capital Employed (%) 6.98 -9.86 -16.09 6.93 2.72 0.87 41.28 9.24 12.33
Return on Assets (%) -0.29 -11.23 -18.19 -1.52 -1.33 -0.95 26.54 4.14 5.64

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 123 95 57 91 946 977 648 707 743
Non Curr. Liab. 105 144 159 278 300 246 227 215 242
Curr. Liab. 330 345 405 406 290 664 431 440 480
Minority Int. 5 5 5 147 2 17 37 40 45
Equity & Liab. 562 589 626 922 1,538 1,904 1,343 1,402 1,509
Non Curr. Assets 352 358 360 612 1,047 1,176 805 796 795
Curr. Assets 210 231 266 310 491 728 538 606 714
Misc. Exp. not W/O
Total Assets 562 589 626 922 1,538 1,904 1,343 1,402 1,509

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 346 327 455 465 625 684 1,031 1,039 1,179
Other Income 10 5 4 10 14 11 17 9 10
Total Income 356 332 459 475 639 695 1,048 1,048 1,189
Total Expenditure -309 -343 -439 -445 -568 -643 -919 -914 -1,009
PBIDT 48 -11 21 30 71 52 129 134 180
Interest -30 -33 -39 -44 -39 -28 -40 -33 -36
Depreciation -23 -29 -33 -33 -46 -40 -53 -42 -51
Taxation 4 8 -1 -3 -3 0 -13 -2 -12
Exceptional Items -59 38 409
PAT -1 -65 -110 -12 -16 -16 431 57 82

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 21 -4 -45 -24 0 -7 45 116 115
Cash Fr. Inv. -67 -55 -80 -155 -316 -116 7 -68 -72
Cash Fr. Finan. 62 35 146 179 309 147 -57 -20 -43
Net Change 17 -24 21 1 -7 24 -5 28 0
Cash & Cash Eqvt 27 3 23 22 20 44 40 68 68

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 56.50 56.50 56.15 56.15 54.87 54.51 53.86 53.86 53.86
Public 43.50 43.50 43.85 43.85 45.14 45.49 46.14 45.54 46.14
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 41.82 70.72 62.12 71.41 44.60 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 30 Jul 2021
Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
Dear Sir/ Madam
In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations 2015 we enclose disclosure of Related Party Transactions on a consolidated
basis in the format specified in the accounting standards for the half year ended March 31 2021.
You are requested to take the same on record.
Thu, 15 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Krunal Shah
Designation :- Company Secretary and Compliance Officer
Thu, 15 Jul 2021
Shareholding for the Period Ended June 30 2021
Sequent Scientific Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Fri, 30 Jul 2021
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
NR 4 Breakdown NR 4 Breakdown
NR 7 Breakdown NR 7 Breakdown

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%